New lung cancer cocktail aims to outperform standard care
NCT ID NCT07583511
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two drug combinations for people with extensive-stage small-cell lung cancer who haven't had prior treatment. One group gets teniposide, cisplatin, and serplulimab; the other gets the standard etoposide, cisplatin, and serplulimab. The goal is to see which combo works better at delaying cancer growth. About 90 participants will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teniposide, cisplatin, serplulimab
What this could lead to
If it works, this could offer a more effective first-line treatment option for extensive-stage small-cell lung cancer, potentially improving how long patients live without their cancer getting worse.
What could go wrong
This is an early phase 2 trial with only 90 people, so results are not definitive. The new combination may not be better than the standard, and could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SUN-YAT-SEN University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact